The protein expression levels of USP1 and PARP1, as well as the acetylation status of USP1-K130, could serve as potential prognostic biomarkers to guide precision stratification therapy in cholangiocarcinoma. This evidence concerns the gene USP1 and cholangiocarcinoma.